Breaks Categories: News

TuesdayDec 13, 2022 3:47 pm

BioMedNewsBreaks – IBN, BioMedWire to Deliver Increased Visibility, Reach for DGE’s 2023 Events

IBN (“InvestorBrandNetwork”), a multifaceted communications organization engaged in connecting companies to the investment community through 50+ brands, has announced that it will collaborate with Dynamic Global Events (“DGE”) as an official media partner for upcoming events in 2023. In addition, BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of IBN’s 50+ brands, will serve as an official media partner for DGE’s events throughout the coming year. A world leader in life sciences-related conference production, DGE has developed a portfolio of high-quality B2B events that facilitate partnership-building, education and networking throughout the pharmaceutical, health care and…

Continue Reading

TuesdayDec 13, 2022 3:41 pm

BioMedNewsBreaks – Keros Therapeutics Inc. (NASDAQ: KROS) Presents Clinical and Preclinical Data from Its Lead Hematological Programs at 64th ASH Event

Keros (NASDAQ: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders, announced that it presented clinical and preclinical data at the 64th American Society of Hematology (“ASH”) Annual Meeting and Exposition. The event was held in person and virtually from Dec. 10 -13, 2022. “We are pleased to present clinical and preclinical data from our lead hematological programs at ASH this year. In our ongoing phase 2 clinical trial in MDS, we observed a sustained response with longer-term treatment with KER-050 across all transfusion burdens.…

Continue Reading

TuesdayDec 13, 2022 2:53 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in ‘Stock2Me’ Podcast

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in the latest episode of the Stock2Me Podcast, an IBN solution to provide specialized content distribution via widespread syndication channels. BiondVax’s CEO Amir Reichman joined the latest episode to introduce the company and discuss its recent development efforts focused on innovative nanosized antibody (“NanoAb”) therapies addressing diseases underserved by current treatments and with large and growing markets. “[While attempting to develop the universal influenza vaccine], BiondVax built a state-of-the-art facility in Jerusalem. It’s a…

Continue Reading

TuesdayDec 13, 2022 10:26 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Interim Chief Financial Officer, Changes Auditor

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announced that Jonathan Tegge, a member of Brio Financial Group, will shoulder the role of interim CFO effective Dec. 12, 2022. The announcement accompanied the news that InMed has signed a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services. A financial and management consulting group based in New Jersey, Brio outsources financial management and financial reporting support to small- and middle-market entities. Currently, the Brio team provides consulting services to some 50 private and publicly traded…

Continue Reading

MondayDec 12, 2022 12:33 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Regains Compliance with Nasdaq Listing Rules

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced the receipt of formal notifications from the Nasdaq Stock Market that the company has regained Nasdaq compliance regarding minimum stockholders’ equity and minimum bid price. The company previously reported receipt of the respective non-compliance notifications on Sept. 30 and Nov. 2, 2022. According to the update, Nasdaq indicated that it has determined, based on BiondVax’s Form 6-K dated Nov. 30, 2022, reporting third-quarter financial results, that the company once again complies with Listing Rule…

Continue Reading

FridayDec 09, 2022 11:26 am

BioMedNewsBreaks – MetAlert Inc. (MLRT) Featured in ‘Stocks to Watch’ by Markets Herald

MetAlert (OTC: MLRT) is a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring. The company was featured in a “Stocks to Watch” report published by Markets Herald, which offers current market trends and analysis across various sectors. “MetAlert (OTC: MLRT) took a significant step forward in the fourth quarter of 2022 by eliminating all toxic convertible notes from its balance sheet,” the publication reads. “This move, along with improved guidance to operations, provides investors with increased stability to the public float. In addition, MetAlert is launching new medical devices geared toward the geriatric and…

Continue Reading

FridayDec 09, 2022 10:23 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in a recent report published by Zacks Small-Cap Research. In the report, Zacks valued BVXV at $57.00/ADS. The publication reads, “On November 30, 2022, BiondVax Pharmaceuticals Ltd. (BVXV) announced financial results for the third quarter of 2022 and provided a business update. The company recently announced positive preclinical results for its inhaled COVID-19 therapy. Using the industry-standard hamster model for COVID-19 therapeutics, results showed that hamsters treated with BiondVax’s NanoAb therapy had significantly (P<0.001)…

Continue Reading

ThursdayDec 08, 2022 11:47 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Preliminary Results from Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released data from its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). The data was presented at the annual meeting for the Society for Neuro-Oncology. Those results indicate that enrolled patients have comparable demographics, including age, gender, race, BSA and KPS; in addition, the percentage of patients continuing on study or having withdrawn is comparable between arms. “Although data are still early, we are pleased with these results in terms of…

Continue Reading

WednesdayDec 07, 2022 2:42 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT) Featured in Research Report

Ludlow Research has announced that it updated its research opinion on MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring. The update is based on MetAlert’s elimination of toxic debt, as well as the launch of new medical device products for cognitive markets. “Toxic debt, or variable convertible notes, are a form of debt, which sometimes convert at deep discounts to market price, and are major contributors to shareholder dilution and price instability for small issuers. In recent months, MetAlert extinguished all of their toxic convertible notes from their balance sheet,…

Continue Reading

WednesdayDec 07, 2022 12:24 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Signs Agreement to Build Exclusive AIMIGo 12-Lead 3D VECG Device

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is partnering with medical device manufacturing company Evolve Manufacturing Technologies to build its credit-card-sized AIMIGo(TM) 3D vector electrocardiogram (“VECG”) recording device; the device is designed to provide a 12-lead ECG readout to detect heart attacks remotely. According to the announcement, HeartBeam will leverage Evolve’s manufacturing and packaging expertise as it focused on commercializing its HeartBeam AIMIGo device; the company expects to receive FDA clearance for the device in early 2023 and will then begin early market…

Continue Reading